Quercetin suppresses lung cancer growth by targeting Aurora B kinase

Cancer Medicine

Volumn 5, Issue 11, 2016, Pages 3156-3165

  Xingyu, Zhu ^a   Peijie, Ma ^b   Dan, Peng ^c   Youg, Wang ^d   Daojun, Wang ^d   Xinzheng, Chen ^e   Xijun, Zhang ^f   Yangrong, Song ^g  

^a SHANXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Baoji Central Hospital   (China)

^c YAN'AN UNIVERSITY   (China)

^d Ankang Central Hospital of Shanxi Province   (China)

^e Baoji city chinese medicine hospital   (China)

^f Chang an Hospital in Xi'an   (China)

^g Department of Internal Medicine   (China)

Author keywords

aurora B; inhibitor; lung cancer cells; quercetin

Indexed keywords

AURORA B KINASE; HISTONE H3; QUERCETIN; ANTINEOPLASTIC AGENT; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

A549 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; EX VIVO STUDY; GROWTH INHIBITION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; JB6 CL41 CELL LINE; LUNG CANCER; LUNG CANCER CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DISEASE MODEL; DRUG RESISTANCE; DRUG SCREENING; EXPERIMENTAL MELANOMA; GENE SILENCING; GENETICS; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AURORA KINASE B; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; QUERCETIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84990179572     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.891     Document Type: Article

References (40)

1. Collins, I., and P. Workman. 2006. New approaches to molecular cancer therapeutics. Nat. Chem. Biol. 2:689–700.
2. Capdeville, R., E. Buchdunger, J. Zimmerman, and A. Matter. 2002. Glivec (STI571), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1:493.
3. González-Loyola, A., G. Fernández-Miranda, M. Trakala, D. Partida, K Samejima, H. Ogawa, et al. 2015. Aurora B Overexpression Causes Aneuploidy and p21Cip1 Repression during Tumor Development. Mol. Cell. Biol. 35:3566–3578.
4. Portella, G., C. Passaro, and P. Chieffi. 2011. Aurora B: a new prognostic marker and therapeutic target in cancer. Curr. Med. Chem. 18:482–496.
5. Yu, J. J., L. D. Zhou, T. T. Zhao, W. Bai, J. Zhou, and W. Zhang. 2015. Knockdown of aurora-B inhibits the growth of non-small cell lung cancer A549 cells. Oncol. Lett. 10:1642–1648.
6. Tovuu, L. O., T. Utsunomiya, S. Imura, Y. Morine, T. Ikemoto, Y. Arakawa, et al. 2014. The role of aurora B expression in non-tumor liver tissues of patients with hepatocellular carcinoma. Int. J. Clin. Oncol. 19:622–628.
7. Keizer, R. J., A. S. Zandvliet, J. H. Beijnen, J. H. Schellens, and A. D. Huitema. 2012. Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152). Invest. New Drugs 30:1519–1530.
8. Dittrich, C., M. A. Fridrik, R. Koenigsberg, C. Lee, R. G. Goeldner, J. Hilbert, et al. 2015. A phase 1 dose escalation study of BI 831266, an inhibitor of aurora kinase B, in patients with advanced solid tumors. Invest. New Drugs 33:409–422.
9. Cheung, C. H., S. Sarvagalla, J. Y. Lee, Y. C. Huang, and M. S. Coumar. 2014. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011–2013). Expert Opin. Ther. Pat. 24:1021–1038.
10. Wienken, C. J., P. Baaske, U. Rothbauer, D. Braun, and S. Duhr. 2010. Protein-binding assays in biological liquids using microscale thermophoresis. Nat. Commun. 1:100.
11. D'Alise, A. M., G. Amabile, M. Iovino, F. P. Di Giorgio, M. Bartiromo, F. Sessa, et al. 2008. Reversine, a novel aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. Mol. Cancer Ther. 7:1140–1149.
12. Vischioni, B., J. J. Oudejans, W. Vos, J. A. Rodriguez, and G. Giaccone. 2006. Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol. Cancer Ther. 5:2905–2913.
13. Smith, S. L., N. L. Bowers, D. C. Betticher, O. Gautschi, D. Ratschiller, P. R. Hoban, et al. 2005. Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br. J. Cancer 93:719–729.
14. Li, X., H. Li, S. Li, F. Zhu, D. J. Kim, H. Xie, et al. 2012. Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting aurora B. Carcinogenesis 33:2548–2557.
15. Visbal, A. L., B. A. Williams, F. C. Nichols, R. S. Marks, J. R. Jett, M. C. Aubry, et al. 2004. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann. Thorac. Surg. 78:209–215.
16. Jackman, D., W. Pao, G. J. Riely, J. A. Engelman, M. G. Kris, P. A. Jänne, et al. 2010. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 28:357–360.
17. Wheeler, D. L., E. F. Dunn, and P. M. Harari. 2010. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 7:493–507.
18. Karachaliou, N., R. Rosell, M. A. Molina, and S. Viteri. 2014. Predicting resistance by selection of signaling pathways. Transl. Lung Cancer Res. 3:107–115.
19. Xie, H., M. H. Lee, F. Zhu, K. Reddy, C. Peng, Y. Li, et al. 2013. Identification of an aurora kinase inhibitor specific for the aurora B isoform. Cancer Res. 73:716–724.
20. Sheng, Y., W. Li, F. Zhu, K. Liu, H. Chen, K. Yao, et al. 2014. 3,6,2′,4′,5′-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer. J. Biol. Chem. 289:28192–2201.
21. Adams, R. R., M. Carmena, and W. C. Earnshaw. 2001. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol. 11:49–54.
22. Li, Y., Z. F. Zhang, J. Chen, D. Huang, Y. Ding, M. H. Tan, et al. 2010. VX680/MK-0457, a potent and selective aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am. J. Transl. Res. 2:296–308.
23. Bischoff, J. R., and G. D. Plowman. 1999. The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol. 9:454–459.
24. Kawasaki, A., I. Matsumura, M. Ji, S. Ezoe, H. Tanaka, Y. Terada, et al. 2001. Downregulation of an AIM-1 kinase couples with megakaryocytic polyploidization of human hematopoietic cells. J. Cell Biol. 152:275–287.
25. Kimura, M., S. Kotani, T. Hattori, N. Sumi, T. Yoshioka, K. Todokoro, et al. 1997. Cell cycle-dependent expression and spindle pole localization of a novel human protein kinase, Aik, related to Aurora of Drosophila and yeast Ipl1. J. Biol. Chem. 272:13766–13771.
26. Farruggio, D. C., F. M. Townsley, and J. V. Ruderman. 1999. Cdc20 associates with the kinase aurora2/Aik. Proc. Natl. Acad. Sci. U S A. 96:7306–7311.
27. Nguyen, H. G., D. Chinnappan, T. Urano, and K. Ravid. 2005. Mechanism of aurora-B degradation and its dependency on intact KEN and A-boxes: identification of an aneuploidy-promoting property. Mol. Cell. Biol. 25:4977–4992.
28. Takeshita, M., T. Koga, K. Takayama, K. Ijichi, T. Yano, Y. Maehara, et al. 2013. Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer. Lung Cancer 80:85–90.
29. Hardwicke, M. A., C. A. Oleykowski, R. Plant, J. Wang, Q. Liao, K. Moss, et al. 2009. GSK1070916, a potent aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol. Cancer Ther. 8:1808–1817.
30. Senft, C., M. Polacin, M. Priester, V. Seifert, D. Kögel, and J. Weissenberger. 2010. The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. BMC Cancer 10:491.
31. Gheorgheosu, D., O. Duicu, C. Dehelean, C. Soica, and D. Muntean. 2014. Betulinic acid as a potent and complex antitumor phytochemical: a minireview. Anticancer Agents Med. Chem. 14:936–945.
32. Liu, J., H. Yu, and X. Ning. 2006. Effect of quercetin on chronic enhancement of spatial learning and memory of mice. Sci. China C. Life Sci. 49:583–590.
33. Mukherjee, A., and A. R. Khuda-Bukhsh. 2015. Quercetin Down-regulates IL-6/STAT-3 Signals to Induce Mitochondrial-mediated Apoptosis in a Nonsmall- cell Lung-cancer Cell Line, A549. J. Pharmacopuncture. 18:19–26.
34. Jiang, W., Y. Huang, N. Han, F. He, M. Li, Z. Bian, et al. 2016. Quercetin suppresses NLRP3 inflammasome activation and attenuates histopathology in a rat model of spinal cord injury. Spinal Cord 54:592–596.
35. Cai, X., L. Bao, X. Dai, Y. Ding, Z. Zhang, and Y. Li. 2015. Quercetin protects RAW264.7 macrophages from glucosamine-induced apoptosis and lipid accumulation via the endoplasmic reticulum stress pathway. Mol. Med. Rep. 12:7545–7553.
36. Liu, Y., Y. M. Wu, and P. Y. Zhang. 2015. Protective effects of curcumin and quercetin during benzo(a)pyrene induced lung carcinogenesis in mice. Eur. Rev. Med. Pharmacol. Sci. 19:1736–1743.
37. Nair, P., A. Malhotra, and D. K. Dhawan. 2015. Curcumin and quercetin trigger apoptosis during benzo(a)pyrene-induced lung carcinogenesis. Mol. Cell. Biochem. 400:51–56.
38. Zhao, X., and J. Zhang. 2015. Mechanisms for quercetin in prevention of lung cancer cell growth and metastasis. Zhong Nan Da Xue Xue Bao Yi Xue Ban 40:592–597.
39. Lee, S. H., E. J. Lee, K. H. Min, G. Y. Hur, S. H. Lee, S. Y. Lee, et al. 2015. Quercetin Enhances Chemosensitivity to Gemcitabine in Lung Cancer Cells by Inhibiting Heat Shock Protein 70 Expression. Clin. Lung Cancer 16:e235–e243.
40. Russo, G. L., M. Russo, C. Spagnuolo, I. Tedesco, S. Bilotto, R. Iannitti, et al. 2014. Quercetin: a pleiotropic kinase inhibitor against cancer. Cancer Treat. Res. 159:185–205.